<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998969</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH-DHLDA5204</org_study_id>
    <nct_id>NCT03998969</nct_id>
  </id_info>
  <brief_title>Efficacy of DA-5204 on Gastroesophageal Reflux Disease</brief_title>
  <official_title>Efficacy of DA-5204 (Stillen 2X®) for Patients With Gastroesophageal Reflux Disease: A Randomized, Double-blind, Placebo-controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double-blind, placebo-controlled clinical Study to
      evaluate the efficacy of DA-5204 and proton pump inhibitor combination therapy compared with
      proton pump inhibitor alone therapy in patients with gastroesophageal reflux Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroesophageal reflux disease is a condition in which reflux of stomach contents into the
      esophagus causes troublesome symptoms, such as heartburn and acid regurgitation.

      Proton pump inhibitors, as acid suppressor, are the agents recommended as the first-line
      treatment for gastroesophageal reflux disease. However, approximately 20-30% of patients have
      insufficient effect on this therapy alone.

      DA-5204 is a medicine based on Artemisia asiatica 95% ethanol extract. DA-5204 has been
      administered to treat gastritis and gastric ulcers with antioxidative and cytoprotective
      actions on gastric mucosal damage. Therefore, we expect DA-5204 to be effective in reflux
      esophagitis (esophageal mucosal injury).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">December 11, 2018</completion_date>
  <primary_completion_date type="Actual">December 11, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endoscopically effective improvement</measure>
    <time_frame>4 weeks</time_frame>
    <description>A percentage of subjects showed effective improvement of erosive esophagitis (esophageal mucosal injury) by the endoscopy.
The definition of &quot;effective improvement&quot; is the subjects showed score changed from 3 to 0, from 2 to 0, or from 3 to 1.
[score 0(LA grade N): normal mucosa, score 1(LA grade M): minimal changes to the mucosa such as erythema, blurring and/or whitish turbidity, score 2(LA grade A): non-confluent mucosal breaks &lt;5 mm in length, score 3(LA grade B): non-confluent mucosal breaks ≥5 mm in length]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endoscopically complete improvement</measure>
    <time_frame>4 weeks</time_frame>
    <description>A percentage of subjects showed complete improvement of erosive esophagitis (esophageal mucosal injury) by the endoscopy.
The definition of &quot;complete improvement&quot; is the subjects showed score changed from 3 to 0 or from 2 to 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom improvement</measure>
    <time_frame>4 weeks</time_frame>
    <description>A percentage of subjects showed sufficient improvement of reflux symptom score from Gastroesophageal Reflux Disease Questionnaire (GerdQ).
The definition of &quot;sufficient improvement&quot; is the subjects showed ≥50% reduction from the initial sum of scores for GerdQ.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Esophageal Disease</condition>
  <arm_group>
    <arm_group_label>Pantoprazole and DA-5204</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pantoprazole 40mg once daily and 'DA-5204' twice daily by mouth, administered for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pantoprazole and placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pantoprazole 40mg once daily and 'placebo' twice daily by mouth, administered for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>Pantoprazole 40mg tablet</description>
    <arm_group_label>Pantoprazole and DA-5204</arm_group_label>
    <arm_group_label>Pantoprazole and placebo</arm_group_label>
    <other_name>Pantoline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-5204</intervention_name>
    <description>DA-5204 tablet</description>
    <arm_group_label>Pantoprazole and DA-5204</arm_group_label>
    <other_name>Stillen 2X®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Film-coated tablet manufactured to mimic DA-5204</description>
    <arm_group_label>Pantoprazole and placebo</arm_group_label>
    <other_name>Placebo (for DA-5204)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age is over 20 years old, under 75 years old, men or women

          -  Patients diagnosed with erosive esophagitis by gastroscopy

          -  Signed the informed consent forms

        Exclusion Criteria:

          -  Patients who is impossible to receive gastroscopy

          -  Patients with esophageal stricture, esophageal varix, Barrett's esophagus, peptic
             ulcer or gastrointestinal bleeding

          -  Patients administered with prokinetics, H2 receptor antagonists, proton pump
             inhibitors, anticholinergic drugs or non-steroid anti-inflammatory drugs prior to
             study in 4 weeks

          -  Patients with surgery related to gastroesophageal

          -  Patients with Zollinger-Ellison syndrome

          -  Patients with any kind of malignant tumor

          -  Patients administered with anti-thrombotic drugs

          -  Patients with significant cardiovascular, pulmonary, heptic, renal, hemopoietic or
             endocrine system primary disease

          -  Patients with neuropsychiatric disorder, alcoholism, or drug abuse

          -  Patients taking other investigational drugs or participating in other clinical studies
             in 4 weeks.

          -  Women either pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Ho Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bungdang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>June 25, 2019</last_update_submitted>
  <last_update_submitted_qc>June 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Dong Ho Lee</investigator_full_name>
    <investigator_title>Director, Clinical Research</investigator_title>
  </responsible_party>
  <keyword>Gastroesophageal Reflux</keyword>
  <keyword>Esophagitis, Peptic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophageal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

